AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
AbbVie's market-beating days don't seem to be over yet.
Overview
AbbVie (NYSE: ABBV), a pharmaceutical giant, is best known for its work in immunology. Over the decade between 2013 (when it became a stand-alone publicly traded company) and 2023, the drugmaker's biggest growth driver was Humira, a medicine for several autoimmune disorders that was once the world's best-selling drug. Humira lost U.S. patent exclusivity in 2023, but since then, Skyrizi and Rinvoq, two other immunology medicines, have become AbbVie's growth pillars.
However, the healthcare leader does have products in other areas that are performing well. One of them is Qulipta, a migraine treatment. And recently, Qulipta achieved a meaningful clinical win that could help boost its sales over the medium term. What does this mean for AbbVie's prospects? Let's find out.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.